Smith & Nephew SNATS Inc
$ 35.97
-0.61%
24 Feb - close price
- Market Cap 15,361,064,000 USD
- Current Price $ 35.97
- High / Low $ 36.44 / 35.89
- Stock P/E 32.60
- Book Value 6.33
- EPS 1.11
- Next Earning Report 2026-02-24
- Dividend Per Share $0.38
- Dividend Yield 2.11 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.09 %
- 52 Week High 38.47
- 52 Week Low 23.71
About
Smith & Nephew plc develops, manufactures, markets and sells medical devices worldwide. The company is headquartered in Watford, the United Kingdom.
Analyst Target Price
$36.42
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-06 | 2025-08-05 | 2025-04-30 | 2025-03-10 | 2024-10-31 | 2024-08-01 | 2024-05-01 | 2024-02-27 | 2023-11-02 | 2023-08-03 | 2023-04-26 |
| Reported EPS | None | 0 | 0.33 | 0 | 0.23 | 0 | 0.756 | 0 | 1.31 | 0 | 0.35 | 0 |
| Estimated EPS | 1.12 | 0 | 1.03 | 0 | 0.97 | 0 | 0.93 | 0 | 0.96 | 0 | 0.81 | 0 |
| Surprise | 0 | 0 | -0.7 | 0 | -0.74 | 0 | -0.174 | 0 | 0.35 | 0 | -0.46 | 0 |
| Surprise Percentage | None% | None% | -67.9612% | None% | -76.2887% | None% | -18.7097% | None% | 36.4583% | None% | -56.7901% | None% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Nov 2025 | May 2025 | Nov 2024 | May 2024 | Nov 2023 | May 2023 | Oct 2022 | May 2022 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-11-07 | 2025-05-28 | 2024-11-08 | 2024-05-22 | 2023-11-01 | 2023-05-17 | 2022-10-26 | 2022-05-11 | None | None |
| Amount | $0.3 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNN
2026-02-23 22:01:22
Smith+Nephew has announced a distribution agreement with SI-BONE for its iFuse TORQ portfolio, which offers breakthrough solutions for percutaneous pelvic fracture fixation procedures. This collaboration aims to expand access to differentiated solutions and strengthen Smith+Nephew's position in high-frequency trauma procedures. The iFuse TORQ TNT implant specifically addresses pelvic fractures and SI joint fusion, holding an FDA Breakthrough Device Designation and eligibility for Medicare New Technology Add-on Payment.
2026-02-23 08:09:17
Worldwide Market Reports has published a comprehensive study on the "Digital Wound Measurement Devices Market," forecasting its growth from 2026 to 2033. The report analyzes market size by manufacturers, regions, types, and applications, and includes an in-depth competitive landscape with key player strategies. It also provides insights into market drivers, challenges, opportunities, and offers essential information for stakeholders and investors.
2026-02-22 11:30:14
Smith & Nephew's relocation from Hull to Melton is causing both delight in the East Riding and disappointment in Hull, exacerbating concerns that new business parks are drawing established companies away from the city. This move will result in the loss of an international brand, numerous skilled jobs for Hull, and poses a significant question mark over the future of Smith & Nephew's current Hessle Road site, which includes extensive adjacent land. The situation highlights a need for comprehensive masterplanning for the area and pressure to improve infrastructure, such as reopening a rail station at Melton.
2026-02-21 12:29:06
Smith+Nephew has received FDA 510(k) clearance for its new Catalystem primary hip system, designed for evolving primary hip surgery demands, including anterior approach procedures and use in ambulatory surgery centers. The system is compatible with the company's Cori surgical robotic platform and features a triple-taper stem design with patent-pending AccuBroach technology for precision and reproducibility. This clearance marks a significant advancement for Smith+Nephew's hip business, aiming to enhance patient outcomes through advanced technology and robotic integration.
2026-02-21 07:54:23
Wall Street Zen has downgraded Smith & Nephew SNATS (NYSE:SNN) from a "strong-buy" to a "buy" rating. Despite this, other firms have weighed in with varying ratings, and the consensus among analysts is a "Hold" with a price target of $35.75. The company's stock is currently trading at $36.10, showing institutional investor interest while analysts recommend holding rather than buying Smith & Nephew SNATS.
2026-02-19 11:58:05
The global Negative Pressure Wound Therapy (NPWT) devices market is projected to grow from $2.9 billion in 2025 to $3.8 billion by 2030, at a compound annual growth rate (CAGR) of 5.9%. This assessment from ResearchAndMarkets.com analyzes the market by product type, application, and end-user, highlighting opportunities in managing diabetic foot ulcers and surgical site infections. The report includes detailed regional analysis, market dynamics, and profiles of key companies such as Solventum, Smith+Nephew, and Cardinal Health.
